Qiagen’s dominant position remains with leadership in fifteen of the eighteen nucleic acid purification segments surveyed

Carlsbad, Calif. – March
1, 2020 – Today Percepta
Associates released its 2020
DNA Purification, Series 1, Life Science Dashboard™ and 2020
RNA Purification, Series 1, Life Science Dashboard™ reports. These reports
update findings from Percepta’s previously published 2016 Nucleic Acid
Purification Dashboard.  2020 reports see
the addition of several new…

Carlsbad, Calif. – November 9, 2016 – Today Percepta Associates released its 2016 Quantitative Immunoassay, Series 3 Life Science Dashboard™ report which draws comparisons to key market indicator data reported in Percepta’s 2013 Series 2 Dashboard report.   This updated dashboard reveals increased usage of all immunoassay methods surveyed except for colorimetric ELISA, with the best growth opportunities in chemiluminescent…

October 7th 2016 –  Percepta Associates Inc. has been selected for the 2016 California Excellence Award for client services in market research among all its peers and competitors by the American Economic Institute (AEI).

Percepta Associates Inc. has consistently demonstrated a high regard for upholding business ethics and company values. This recognition by AEI marks a significant achievement as an emerging…

In a recent summary of the presumptive presidential nominees’ positions on issues related to science and the environment including GMO labeling, global climate change and fossil fuels, there was a clear dichotomy.  That is not likely to surprise many in an election year.  However, we were interested in seeing what actual scientists thought of these “Science and Environment” political issues.

Percepta polled…

Qiagen’s dominant position has eroded in seven of the fifteen segments surveyed, resulting in other suppliers share gain

Carlsbad, Calif. – On June 30th Percepta Associates released its 2016 Nucleic Acid Purification, Series 5 Life Science Dashboard™ report which draws comparisons to key market indicator data reported in Percepta’s 2013 Series 4 Dashboard report.   This updated dashboard reveals a significant…

Today Percepta Associates released its 2016 Protein Electrophoresis and Western Analysis, Series 3 Life Science Dashboard™ market research report which draws comparisons to key market indicator data reported in Percepta’s 2013 Series 2 Dashboard.   This updated dashboard reveals an increase in growth rates for 6 of the 7 product categories surveyed compared to 2013 findings, with highest anticipated growth…

In this campaign year, politicians have once again started to consider the issue of regulating pharmaceutical pricing policies.  It’s not a new concept but recent practices of certain pharmaceutical companies have given this topic new life.

An article in The New York Times on October 4th reported on several pharmaceutical companies that were buying existing patented therapeutic drugs and dramatically…

Percepta Associates Inc., a leading provider of market research for the biotools industry, today announced the opening of new offices in Seattle.  The new office space is in the Madrona Business Plaza located at 1421 34th Ave., Seattle, WA  98122 and will provide a second west coast center of operations.

“Percepta’s new offices in Seattle will allow us to expand capabilities beyond our current…

If there is something new to learn about the immune related brain disorders – this is it.  Scientist at the University of Virginia School of Medicine have determined that the brain is directly connected to the immune system by vessels previously thought not to exist.  read more

Approximately 570 diagnostic tests and testing systems have been approved by the FDA for exclusion from regulation under CLIA criteria.  These tests are referred to as CLIA waived tests.

Roughly 4% of all CLIA waived tests in existence in the United States are HIV tests or test systems. Though all CLIA waived tests, including HIV tests, are designed to be…